Merck
  • Home
  • Search Results
  • Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma.

Dynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastoma.

PloS one (2014-10-01)
Cecilie Brekke Rygh, Jian Wang, Marte Thuen, Andrea Gras Navarro, Else Marie Huuse, Frits Thorsen, Aurelie Poli, Jacques Zimmer, Olav Haraldseth, Stein Atle Lie, Per Øyvind Enger, Martha Chekenya
ABSTRACT

There are currently no established radiological parameters that predict response to immunotherapy. We hypothesised that multiparametric, longitudinal magnetic resonance imaging (MRI) of physiological parameters and pharmacokinetic models might detect early biological responses to immunotherapy for glioblastoma targeting NG2/CSPG4 with mAb9.2.27 combined with natural killer (NK) cells. Contrast enhanced conventional T1-weighted MRI at 7±1 and 17±2 days post-treatment failed to detect differences in tumour size between the treatment groups, whereas, follow-up scans at 3 months demonstrated diminished signal intensity and tumour volume in the surviving NK+mAb9.2.27 treated animals. Notably, interstitial volume fraction (ve), was significantly increased in the NK+mAb9.2.27 combination therapy group compared mAb9.2.27 and NK cell monotherapy groups (p = 0.002 and p = 0.017 respectively) in cohort 1 animals treated with 1 million NK cells. ve was reproducibly increased in the combination NK+mAb9.2.27 compared to NK cell monotherapy in cohort 2 treated with increased dose of 2 million NK cells (p<0.0001), indicating greater cell death induced by NK+mAb9.2.27 treatment. The interstitial volume fraction in the NK monotherapy group was significantly reduced compared to mAb9.2.27 monotherapy (p<0.0001) and untreated controls (p = 0.014) in the cohort 2 animals. NK cells in monotherapy were unable to kill the U87MG cells that highly expressed class I human leucocyte antigens, and diminished stress ligands for activating receptors. A significant association between apparent diffusion coefficient (ADC) of water and ve in combination NK+mAb9.2.27 and NK monotherapy treated tumours was evident, where increased ADC corresponded to reduced ve in both cases. Collectively, these data support histological measures at end-stage demonstrating diminished tumour cell proliferation and pronounced apoptosis in the NK+mAb9.2.27 treated tumours compared to the other groups. In conclusion, ve was the most reliable radiological parameter for detecting response to intralesional NK cellular therapy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Interleukin-2 human, IL-2, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Monoclonal Anti-HLA-G-PE antibody produced in mouse, clone 87G, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-HLA-G-PE antibody produced in mouse, clone MEM-G/9, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Interleukin-2 human, recombinant, expressed in Pichia pastoris, suitable for cell culture
Sigma-Aldrich
Interleukin-2 human, IL-2, recombinant, expressed in HEK 293 cells, suitable for cell culture, endotoxin tested
Sigma-Aldrich
IL-2 human, Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sigma-Aldrich
IL-2 human, recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE)
Sigma-Aldrich
Interleukin-2 human, recombinant, expressed in E. coli, ~10000 U/mL